Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation?

European Economic Review

Volumn 53, Issue 2, 2009, Pages 170-185

  Brekke, Kurt R ^a   Grasdal, Astrid L ^b   Holmås, Tor Helge ^b  

^a NORWEGIAN SCHOOL OF ECONOMICS   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Branded generic competition; Pharmaceuticals; Price regulation

Indexed keywords

COMMODITY PRICE; COMPETITION (ECONOMICS); DATA SET; DRUG; ESTIMATION METHOD; POLICY ANALYSIS; PRICE DYNAMICS; REGULATORY FRAMEWORK;

EURASIA; EUROPE; NORTHERN EUROPE; NORWAY; SCANDINAVIA;

EID: 61849162196     PISSN: 00142921     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroecorev.2008.03.004     Document Type: Article

References (31)

1. Aronsson T., Bergman M.A., and Rudholm N. The impact of generic drug competition on brand name market shares-evidence from micro data. Review of Industrial Organization 19 (2001) 425-435
2. Ashenfelter O. Estimating the effect of training programs on earnings. Review of Economics and Statistics 67 (1978) 47-57
3. Bergman M.A., and Rudholm N. The relative importance of actual and potential competition: Empirical evidence from the pharmaceuticals market. Journal of Industrial Economics LI (2003) 455-467
4. Bommier A., Jullien B., and Bardey D. Retail price regulation and innovation: Reference pricing in the pharmaceutical industry (2006), Mimeo, University of Toulouse
5. Brekke K.R., Königbauer I., and Straume O.R. Reference pricing of pharmaceuticals. Journal of Health Economics 26 (2007) 613-642
6. Card D., and Sullivan D.G. Measuring the effect of subsidized training programs on movement in and out of employment. Econometrica 56 (1988) 497-530
7. Caves R.E., Whinston M.D., and Hurwitz M.A. Patent expiry, entry and competition in the US pharmaceutical industry. Brookings papers on economic activity. Microeconomics (1991) 1-48
8. Contoyannis P., Hurley J., Grootendorst P., Jeon S.-H., and Tamblyn R. Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: An illustration from Quebec Canada. Health Economics 14 (2005) 909-923
9. Dalen D.M., Strøm S., and Haabeth T. Price regulation and generic competition in the pharmaceutical market. European Journal of Health Economics 7 (2006) 208-214
10. Danzon P.M. Pharmaceutical Price Regulation: National Policies versus Global Interests (1997), American Enterprise Institute Press, Washington
11. Danzon P.M. Reference pricing: Theory and evidence. In: Lopez-Casasnovas G., and Jönsson B. (Eds). Reference Pricing and Pharmaceutical Policy (2001), Springer, Barcelona (Chapter 5)
12. Danzon P.M., and Ketcham J.D. Reference pricing of pharmaceuticals for Medicare: Evidence from Germany, The Netherlands and New Zealand. In: Cutler D.M., and Garber A.M. (Eds). Frontiers in Health Policy Research vol. 7 (2004), National Bureau of Economic Research, MIT Press, Cambridge, MA
13. Danzon, P.M., Liu, H., 1996. RP and physician drug budgets: The German experience in controlling pharmaceutical expenditures. Working Paper, The Wharton School.
14. Ellison S.F., Cockburn I., Griliches A., and Hausman J. Characteristics of demand for pharmaceutical products: An examination of four cephalosporins. RAND Journal of Economics 28 (1997) 426-446
15. Frank R.G., and Salkever D.S. Pricing patent loss and the market for pharmaceuticals. Southern Economic Journal 59 (1992) 165-179
16. Frank R.G., and Salkever D.S. Generic entry and the market for pharmaceuticals. Journal of Economics & Management Strategy 6 (1997) 75-90
17. Golec, J.H., Vernon, J., 2006. European pharmaceutical price regulation, firm profitability, and R&D spending. NBER Working Paper 12676.
18. Grabowski H.G., and Vernon J. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics 35 (1992) 331-350
19. Huskamp H.A., Rosenthal M.B., Frank R.G., and Newhouse J.P. The Medicare prescription drug program: How will the game be played?. Health Affairs 19 2 (2000) 18-23
20. Kanavos, P., 2001. Overview of pharmaceutical pricing and reimbursement regulation in Europe. Commission of the European Communities, Dg Enterprise, November.
21. Kanavos P., and Reinhardt U. Reference pricing for drugs: Is it compatible with U.S. health care. Health Affairs 22 3 (2003) 16-30
22. Königbauer I. Advertising and generic market entry. Journal of Health Economics 26 (2007) 286-305
23. Lavy V. Evaluating the effect of teachers' group performance incentives on pupil achievement. Journal of Political Economy 110 (2002) 1286-1317
24. Leibowitz A., Manning W.G., and Newhouse J.P. The demand for prescription drugs as a function of cost-sharing. Social Science and Medicine 21 (1985) 1063-1069
25. Lopez-Casasnovas G., and Puig-Junoy J. Review of the literature on reference pricing. Health Policy 54 (2000) 87-123
26. Pavcnik N. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?. RAND Journal of Economics 33 3 (2002) 469-487
27. Puig-Junoy J. What is required to evaluate the impact of pharmaceutical reference pricing?. Applied Health Economics & Health Policy 4 (2005) 87-98
28. Rizzo J.A. Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. Journal of Law and Economics 42 (1999) 89-116
29. Scherer F.M. The link between gross profitability and pharmaceutical R&D spending. Health Affairs 20 (2001) 216-220
30. Scherer F.M. A note on global welfare in pharmaceutical patenting. World Economy 27 (2004) 1127-1142
31. Zweifel P., and Crivelly L. Price regulation of drugs: Lessons from Germany. Journal of Regulatory Economics 10 (1996) 257-273